Faslodex (fluvestrant)

April 5, 2019

Faslodex-Arimidex Improves Survival in Post-menopausal Women with Advanced BC, Trial Shows

News

First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results of ... Read more

November 5, 2018

Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows

News

Adding Pfizer’s Ibrance (palbociclib) to standard treatment Faslodex (fulvestrant) significantly extended the survival of advanced breast cancer patients in a Phase 3 clinical trial, researchers report. Called PALOMA-3, the trial (NCT01942135) specifically ... Read more

September 5, 2017September 5, 2017

FDA Approves Faslodex As First-Line Therapy for HR+, HER2– Advanced Breast Cancer

News

The U.S. Food and Drug Administration has approved Faslodex (fulvestrant) as a first-line treatment for patients with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, therapy ... Read more

January 13, 2017

Enzymes’ Role in Development, Treatment of Estrogen Receptor-positive Cancer Identified

News

Researchers have identified two new factors that may help to determine whether a patient with estrogen receptor-positive breast cancer will respond to treatment. In addition to preventing the estrogen receptor from ... Read more